Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection
Ata S. Moshiri,Ryan Doumani,Lola Yelistratova,Astrid Blom,K. Lachance,Michi M. Shinohara,Martha A. Delaney,Oliver H. Chang,Susan McArdle,Hannah Thomas,Maryam M. Asgari,Meei Li Huang,Stephen M. Schwartz,Paul Nghiem,Paul Nghiem +14 more
TLDR
It is confirmed that approximately 20% of MCCs are not driven by MCPyV and that such virus-negative M CCs, which can be quite reliably identified by immunohistochemistry using the CM2B4 antibody alone, represent a more aggressive subtype that warrants closer clinical follow-up.About:
This article is published in Journal of Investigative Dermatology.The article was published on 2017-04-01 and is currently open access. It has received 194 citations till now. The article focuses on the topics: Merkel cell polyomavirus & Merkel cell carcinoma.read more
Citations
More filters
Journal ArticleDOI
Merkel cell carcinoma.
Jürgen C. Becker,Andreas Stang,James A. DeCaprio,Lorenzo Cerroni,Céleste Lebbé,Michael J. Veness,Paul Nghiem +6 more
TL;DR: Excision of the tumour is the first-line therapy; if not feasible, radiotherapy can often effectively control the disease, and Chemotherapy was the only alternative in advanced-stage or refractory MCC until several clinical trials demonstrated the efficacy of immune-checkpoint inhibitors.
Journal ArticleDOI
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,William H. Sharfman,Ragini R. Kudchadkar,Andrew S. Brohl,Phillip A. Friedlander,Adil Daud,Harriet M. Kluger,Sunil Reddy,Brian C. Boulmay,Adam I. Riker,Melissa Amber Burgess,Brent A. Hanks,Thomas Olencki,Kim Margolin,Lisa Lundgren,Abha Soni,Nirasha Ramchurren,Candice D. Church,Song Youn Park,Michi M. Shinohara,Bob Salim,Janis M. Taube,Steven R. Bird,Nageatte Ibrahim,Steven P. Fling,Blanca Homet Moreno,Elad Sharon,Martin A. Cheever,Suzanne L. Topalian +30 more
TL;DR: There was a trend toward improved PFS and OS in patients with programmed death ligand-1-positive tumors, and Pembrolizumab demonstrated durable tumor control, a generally manageable safety profile, and favorable OS compared with historical data from patients treated with first-line chemotherapy.
Journal ArticleDOI
The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
Paul W. Harms,Kelly L. Harms,Patrick S. Moore,James A. DeCaprio,Paul Nghiem,Michael K K Wong,Isaac Brownell +6 more
TL;DR: The availability of immune checkpoint inhibition has improved the outcomes of a subset of patients with MCC, although many unmet needs continue to exist, according to this Consensus Statement.
Journal ArticleDOI
Merkel cell carcinoma: An update and review: Pathogenesis, diagnosis, and staging.
TL;DR: A comprehensive review of MCC epidemiology, pathogenesis, clinical presentation, diagnostic evaluation and prognostic markers is provided and the evolving landscape in MCC management is explored.
Journal ArticleDOI
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian,Shailender Bhatia,Asim Amin,Ragini R. Kudchadkar,William H. Sharfman,Céleste Lebbé,Jean Pierre Delord,Lara Dunn,Michi M. Shinohara,Rima M. Kulikauskas,Christine H. Chung,Uwe M. Martens,Robert L. Ferris,Julie E. Stein,Elizabeth L. Engle,Lot A. Devriese,Christopher D. Lao,Junchen Gu,Bin Li,Tian Chen,Adam Barrows,Andrea Horvath,Janis M. Taube,Paul Nghiem +23 more
TL;DR: Nivolumab administered approximately 4 weeks before surgery in MCC was generally tolerable and induced pCRs and radiographic tumor regressions in approximately one half of treated patients, and early markers of response significantly predicted improved RFS.
References
More filters
Journal ArticleDOI
Clonal integration of a polyomavirus in human Merkel cell carcinoma.
TL;DR: In six of eight MCV-positive MCCs, viral DNA was integrated within the tumor genome in a clonal pattern, suggesting that MCV infection and integration preceded clonal expansion of the tumor cells, and MCV may be a contributing factor in the pathogenesis of MCC.
Journal Article
Prognostic and predictive factors in breast cancer by immunohistochemical analysis
TL;DR: Although available studies suggest that estrogen and progesterone receptors might indeed be helpful in making treatment decisions, their clinical usefulness is still controversial, and there are important unresolved technical issues, such as how to prepare the tissue, which reagents to use and, most importantly, how to interpret the results.
Journal ArticleDOI
Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions
TL;DR: Because UDG does not react with dUTP, and is also inactivated by heat denaturation prior to the actual PCR, carry-over contamination of PCRs can be controlled effectively if the contaminants contain uracils in place of thymines.
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.
Journal ArticleDOI
Merkel cell carcinoma and HIV infection.
TL;DR: It is suggested that immune suppression induced by the human immunodeficiency virus increases MCC risk.
Related Papers (5)
Clonal integration of a polyomavirus in human Merkel cell carcinoma.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more